JPM vs PFE: Which Is the Better Buy?

Side-by-side comparison of JPMorgan Chase & Co. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
JPMorgan Chase & Co. · Financial Services
$309.87
-6.4% upside to fair value
High Conviction Grade A-
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric JPM PFE
Current Price $309.87 $26.91
Fair Value Estimate $290.00 $35.00
Upside to Fair Value -6.4% +30.1%
Market Cap $835.7B $153.0B
Forward P/E 14.3x 9.5x
EV / EBITDA 17.6x 13.8x
Price / Sales 3.0x 2.4x
Price / FCF 16.8x
Revenue Growth YoY +3.3% -1.6%
Gross Margin 59.99% 70.3%
Operating Margin 25.9% 24.7%
Return on Equity 15.95% 9.0%
Dividend Yield 1.9% 6.4%
FCF Yield 5.9%
Analyst Consensus Overweight Hold
Investment Thesis
JPM — JPMorgan Chase & Co.
JPMorgan Chase is the largest U.S. bank by assets ($4.4T) and the most diversified financial services franchise globally, operating across consumer banking, investment banking, commercial banking, and asset management. Under Jamie Dimon's two-decade leadership, the firm has consistently gained market share, delivered sector-leading ROE of 16%, and invested aggressively in technology ($17B+ annual…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric JPM PFE
Zone Low $220.00 $25.00
Zone High $250.00 $29.00
In Buy Zone? No Yes
← JPM Research    PFE Research →    All Research